Letters
Drug payments and regional prescribing
Authors’ reply to Ramachandran
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i5255 (Published 29 September 2016) Cite this as: BMJ 2016;354:i5255
- William Fleischman, clinical scholar1,
- Joseph S Ross, associate professor2,
- Shantanu Agrawal, deputy administrator3
- 1Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Medicine, 333 Cedar Street, SHM-IE 61, New Haven, CT 06510, USA
- 2Section of General Internal Medicine, Department of Medicine, Yale School of Medicine, New Haven, CT, USA
- 3Center for Medicare and Medicaid Services, Department of Health and Human Services, Washington, DC, USA
- wf3{at}buffalo.edu
Prompted by the recently proposed US amendment S.2978 to exempt from mandatory reporting through the Open Payments program any payments from drug manufacturers to physicians related to physician education,1 Ramachandran asks whether we conducted analyses examining the association between prescribing and any payments related to educational materials.2 3
In response, we performed a subgroup analysis focused on payments for continuing medical education (CME) speaker fees and for educational materials, including journal articles and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.